Indication
Gastroenteropancreatic Neuroendocrine Tumor
6 clinical trials
10 products
1 drug
Product
LanreotideClinical trial
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NETStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
CAM2029Product
OctreotideClinical trial
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETStatus: Active (not recruiting), Estimated PCD: 2023-07-20
Product
LutatheraProduct
Long-acting octreotideProduct
Long-acting OctreotideProduct
68Ga-DOTATOCClinical trial
An Open-label, Single Arm Clinical Trial of Gallium (68Ga) Edotreotide PET-CT Scan for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine TumorsStatus: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Status: Recruiting, Estimated PCD: 2026-12-01
Product
Lutetium OxodotreotideProduct
CVM-1118Clinical trial
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine TumorsStatus: Withdrawn, Estimated PCD: 2024-04-23
Drug
LutatheraProduct
Azedra